...
首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >A clinical comparative study on the effects of metformin and pioglitazone on clinical symptoms in cases of polycystic ovarian syndrome
【24h】

A clinical comparative study on the effects of metformin and pioglitazone on clinical symptoms in cases of polycystic ovarian syndrome

机译:二甲双胍和吡格列酮对多囊卵巢综合征患者临床症状影响的临床比较研究

获取原文
           

摘要

Background: The present study was aimed to evaluate the efficacy of pioglitazone and comparing the efficacy of pioglitazone with metformin in improvement of clinical characteristics of the PCOS patients. Methods: The present study was a prospective, parallel group trial in 40 proven cases of PCOS, all the patients underwent clinical evaluations at baseline that include height, weight, BMI, waist to hip ratio (WHR) and hirsutism (FG score). There were two groups in this study group A (unmarried) and group B (married) each divided in two subgroups each having 10 patients, A1 (unmarried - metformin), A2 (unmarried - pioglitazone), B1 (married - metformin), B2 (married - pioglitazone) therapy was given for six months with regular clinical evaluation of the patients after every two months. WHR (Waist to hip ratio) was measured according to World Organization Criteria (2003), BMI was calculated by using Quetelets Index formula WHO (1995), the grade of hirsutism was detected using Ferriman-Gallwey score (1961). Results: On comparing metformin and pioglitazone it was observed that both the drugs equally decreased the FG score; metformin significantly decreased the BMI and WHR whereas pioglitazone significantly increased the BMI and WHR. Conclusions: Pioglitazone significantly increased the BMI and WHR, whereas it significantly decreased FG score. On comparing metformin and pioglitazone it was observed that both the drugs equally decreased the FG score, metformin significantly decreased the BMI and WHR whereas pioglitazone significantly increased the BMI and WHR.
机译:背景:本研究旨在评估吡格列酮的疗效,并比较吡格列酮与二甲双胍在改善PCOS患者临床特征方面的功效。方法:本研究是一项前瞻性,平行组试验,在40例确诊的PCOS病例中,所有患者均在基线进行了临床评估,包括身高,体重,BMI,腰臀比(WHR)和多毛症(FG评分)。该研究分为两组(A组(未婚)和B组(已婚)),每组分为两个亚组,每组分别有10名患者,A1(未婚-二甲双胍),A2(未婚-吡格列酮),B1(已婚-二甲双胍),B2给予(已婚-吡格列酮)治疗六个月,每两个月对患者进行定期临床评估。根据世界组织标准(2003)测量WHR(腰围与臀部的比率),使用Quetelets指数公式WHO(1995)计算BMI,使用Ferriman-Gallwey评分(1961)检测多毛症的等级。结果:在比较二甲双胍和吡格列酮时,发现两种药物均会降低FG评分。二甲双胍显着降低BMI和WHR,而吡格列酮显着增加BMI和WHR。结论:吡格列酮显着增加了BMI和WHR,而显着降低了FG评分。比较二甲双胍和吡格列酮后,观察到两种药物均会降低FG评分,二甲双胍显着降低BMI和WHR,而吡格列酮则显着提高BMI和WHR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号